US Patent

US11833166 — Pharmaceutical composition, methods for treating and uses thereof

Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2034-04-03 · 8y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using a certain SGLT-2 inhibitor, such as Jardiance, to treat or prevent metabolic disorders in patients with renal impairment or chronic kidney disease.

USPTO Abstract

The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3777 — Jardiance
U-3777 — Jardiance
U-3776 — Jardiance
U-3776 — Jardiance
U-3776 — Jardiance
U-3776 — Jardiance
U-3777 — Jardiance
U-3777 — Jardiance
U-3776 — Jardiance
U-3777 — Jardiance
U-3777 — Jardiance
U-3776 — Jardiance
U-3777 — Jardiance
U-3776 — Jardiance
U-3777 — Jardiance
U-3776 — Jardiance

Patent Metadata

Patent number
US11833166
Jurisdiction
US
Classification
Method of Use
Expires
2034-04-03
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.